Drug Profile
TDM 812
Alternative Names: TDM812Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator 3-D Matrix
- Developer 3-D Matrix; National Cancer Center (Tokyo); National Cancer Research Institute
- Class Antineoplastics; Nucleic acids, nucleotides, and nucleosides; Peptides; Small interfering RNA
- Mechanism of Action RNA interference; Small interfering RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Triple negative Breast-cancer(Inoperable/Unresectable, Refractory metastatic disease, Second-line therapy or greater) in Japan (Intratumoural)